PPARG and diabetes mellitus: To date, only scattered evidence is available at the clinical level for a potential therapeutic value of PPARγ agonists in MS, with reports available exclusively about pioglitazone, a drug approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus.